Aim. To study ESBL phenotypes, as well as to identify individual genotypes of β-lactamases and to study their prevalence among clinical strains of Enterobacteriaceae collected from children with congenital heart diseases. Methods. Clinical strains of Enterobacteriaceae were studied in order to determine their susceptibility to antibiotics, using an automated system, before genotyping resistance determinants using multiplex PCR. Results. During the period of the study, 10.9 % of ESBL-positive isolates were found among clinical strains of Enterobacteriaceae. Most ESBL-producing strains (33.3 %) were Klebsiella pneumoniae. Most strains producing extended-spectrum β-lactamases were isolated from the respiratory tract and accounted for 83.3 %. Conclusions. An experimental study provided new data as regards the prevalence of ESBL-producing genetic resistance determinants within the Enterobacteriaceae family, and their role in the development of complications. For the first time in Ukraine, we performed genotyping Multiplex PCR-based genotyping tests of ESBLpositive isolates. The study showed diagnostic value of molecular biological methods in identifying resistance determinants of microorganisms.
Introduction
Acquired antibiotic resistance of the Enterobacteriaceae represents globally escalating problem in treatment of healthcare-associated infections. The rapid evolution of bacterial resistance among Enterobacteriaceae to the beta-lactam class of antibiotics has reached epidemic proportions [1] . The background component of this growing resistance Biomedicine ISSN 1993-6842 (on- is the expression of enzymes known as extended-spectrum β-lactamases (ESBL) by a bacterial cell. These enzymes are generally defined as beta-lactamases and confer bacterial resistance to penicillins, first-, second-, third-ge ne ra tion cephalosporins and to aztreonam, but not the carbapenems and cephamycins [2] . Widespread use of these groups of antibiotics has led to the expansion of β-lactamaseencoding genes in Enterobacteriaceae like TEM, CTX-M, and SHV which can be encoded on mobile genetic elements, including plasmids and transposons that also often encrypt adventive resistance genes including multiple classes of antibiotics [3] .
Risk factors for ESBL infection development are patient's age, prolonged in-hospital stay and previous stay at an intensive care unit (ICU) stay, prior use of antibiotics, and indwelling devices such as urinary catheters, central venous catheters, tracheostomy, and endotracheal tubes [4] .
ESBL-related hospital infections are associated with negative outcomes for patients, resulting in prolonged hospital stay, increased hospitalization / inpatient costs, and increased morbidity rates [2] . The main driver of this increased morbidity is insufficient antibiotic therapy. So, early monitoring of groups of surgical patients who are at risk for infection by ESBL-producing bacteria is crucial for a choice of antibiotic treatment strategy and important point for infection spread control.
Modern data indicate a growing prevalence of ESBL's isolated from different patient groups globally [5] [6] [7] [8] [9] [10] . However, neither single-nor multicenter studies have been conducted on ESBL-related hospital infections in Ukraine. The resistance is determined by the expression of bla genes belonging to bla TEM , bla SHV , and bla CTX-M genes family. To date, CTX-M enzymes are characterized as the most clinically important groups of ESBLs, which is followed by SHV-and TEM-derived ESBLs. The bla TEM , bla SHV , and bla CTX-M genes are responsible for production of evolutionarily relative enzymes -TEM β-lactamases, SHV β-lactamases, and CTX-M β-lactamases, respectively. To date, there are about 100 derivatives of TEM-1 enzymes; 185 new β-lactamases of the TEM family have been reported worldwide, while only ninety-three variants are responsible for production of ESBLs. According to data reported recently, among one hundred seventy-two types of SHV family of enzymes, forty-five were represen ted as extended-spectrum beta-lactamases. The CTX-M family includes more than sixty enzymes (http: //www.eucast.org/clinical breakpoints).
Multiple molecular typing methods, including PCR-based assays, have been developed for detection and identification of the growing number of bla TEM , bla SHV and bla CTX-M genes. Though, there is still limited scientific data on epidemiology of ESBL spread in the Ukraine. To the best of our knowledge, this is the first study on the molecular epidemiology and antimicrobial susceptibilities of ESBL-producing Enterobacteriaceae among surgical patients in Ukraine.
The purpose of this study was to explore feasibility of simultaneous identification of bla TEM , bla SHV and bla CTX-M genes by multiplex PCR detection in a series of clinical isolates of Enterobacteriaceae with previously characterized ESBL phenotype, to im-plement routing monitoring of ESBLproducing Enterobacteriaceae strains at the Ukrainian Children's Cardiac Center (Kyiv, Ukraine), to determine predominant genotypes among ESBL-producing Enterobacteriaceae strains.
Materials and Methods
All study strains were selected based on the screening tests for the detection of ESBL-type enzymes. The isolates were collected from clinical specimens of patients hospitalized at the Ukrainian Children's Cardiac Center (Kyiv, Ukraine) during the period from January to December, 2015. The isolates were recovered from various clinical specimens, mostly tracheal discharges, throat swabs, wounds, urine and blood. The majority of the collected strains were obtained during cardiac surgery in 704 patients representing different regions of Ukraine. The average age in the studies was 128 ± 106.5 days (0 days to 1 year) ( Table 1) .
The ESBL phenotype of the bacterial strains was determined by the VITEK 2 GN cards and the automated identification system (bio Merieux, France) in accordance with internal SOPs and manufacturer's protocols.
Testing of antibiotic susceptibility and ESBL determination
Susceptibility of clinical isolates to β-lactams (ampicillin, cefazolin, cefuroxime, cefepime, ceftriaxone, imipenem, and meropenem) and to ciprofloxacin, amikacin, ofloxacin, levofloxacin, tobramycin, and trimethoprim / sulfamethoxazole was tested by using AST-N076 cards and the automated VITEK 2 system. Susceptibility was interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendations (http://www.eucast.org/clinicalbreakpoints). Thirty Enterobacteriaceae strains including twenty-two strains of K. pneumoniae, four strains of E.coli, and four strains of other Enterobacteriaceae from hospitalized patients were found to be ESBL producers. The presen ce of ESBL phenotype was confirmed by VITEK 2 automated system.
DNA isolation
Purified DNA from overnight bacterial cultures was isolated using the QIAGEN DNeasy Blood and Tissue Kit (Catalog# 69504) and NucleoSpin® Blood QuickPure kit (MACHEREY NAGEL, Germany). Qualitative analysis of DNA was performed by electrophoresis in 1 % agarose gel with 0.5 % TBE buffer (Tris-Borate-EDTA).
Multiplex PCR amplification
Multiplex PCR-based genotyping tests were conducted on thirty ESBL-positive isolates (Table 1) including twenty-two strains of K. pneumoniae, four strains of E.coli, and four strains of other Enterobacteriaceae (Enterobac ter cloacae, Serratia marcescens and Klebsiella oxytoca).
For genotyping tests, we used sequence primers-pair and technique of multiplex PCR, with some modifications, described previously [11] .
Primer-pair sequences (bla-SHV.SE/AS; TEM-164.SE and TEM-165.AS; universal CTX-M-U1/U2) used in the multiplex PCR and assay PCR amplicon sizes are given in Table 2 . The reaction mixtures contained 1× PCR buffer, 200 µM dNTP, 0.5 unit of Taq PCR amplicons were separated electrophoretically in 2 % (w/w) agarose gel containing 0.5 µg/ml ethidium bromide (Sigma Aldrich, USA) and 0.5 % TBE buffer and visualized with «DOC-Print VX2» (Vilber Lourmat) system.
Results and Discussion
In this study, we examined the prevalence of ESBL producing Enterobacteriaceae and carried out molecular characterization and antimicrobial susceptibility testing of clinical samples from patients during their admission to the cardiac hospital.
ESBL-producing Enterobacteriaceae were obtained from clinical specimens of patients representing different regions of Ukraine (30.0 % were from Kyiv, 13.3 % were from Zhytomyr, 13.3 % were from Volyn, 10.0% were from Lviv, 10.0% were from Vinnytsa, 6.6 % were from Odessa, 6.6 % were from Donetsk, 3.3 % were from Ivano-Frankivsk, 3.3 % were from Zaporizhia and 3.3 % were from Dnipro) hospitalized at the Ukrainian Children's Cardiac Center (Kyiv, Ukraine).
During the study period, total of 30 (10.9 %) ESBL-producing Enterobacteriaceae were isolated. The demographic profile of the studi ed population was summarized. It shows that 56.6 % (n = 17) of ESBL-positive samples were collected from male patients and 43.3 % (n = 13) of samples were from female patients (Table 1) . Among the isolates, K. pneumoniae (33.3 %, n = 22) was prevalent ESBLproducing bacteria, ESBL-phenotype of E. coli accounted for 13.3 % (n = 4), and other ESBLproducing Enterobacteriaceae accounted for 13.3 % (n = 4). These pathogens were isolated from a variety of clinical samples, respiratory system -83.3 % (n = 25), blood -6.6 % (n = 2), and others -10.0 % (n = 3).
In our study, the main ESBL producers were found to be K. pneumoniae and E. coli and other species, which is consistent with previously published results [9, 14, 15] , overall part of ESBL-producing pathogens among Ente robac teriaceae strains was substantially lower (10.9 %) than that reported in other studies in other geographical regions [14, 15] and higher than reported in other hospital-associated infection studies [11, 13] . The majority of CTX-M-U1 CTX-M-U2 atgtgcagyaccagtaargtkatggc tgggtraartargtsaccagaaycagcgg 593 [11, 13] these infections were due to E. coli rather than Klebsiella pneumoniae, as described in the non-transplant literature in many cases and as was observed in our study. However, during screening of 1065 patients at the UCLA Medical Center who had undergone heart or lung transplantation between 1996 and 2010, the incidence of ESBL-related infections in these groups appeared to be 2.2 %, 5.5 %, and 10.7 % of patients, respectively [13] . It can be explained by methodological differences in the measured prevalence levels, difference in age groups of patients and time-depended distribution of resistance. In this study, the respiratory tract was the major source of ESBL-producing isolates, followed by the blood and other sampling media. Similar findings have previously been repor ted for the ICUs at hospitals in Mexico, India and Qatar where the major source of ESBLproducing isolates were the respiratory tract and blood [9, 16, 17] . However, in other geographical regions, urine and blood were reported as the major source of ESBL-producing bacteria [6, 12] .
The antibiotic susceptibilities of ESBLproducers are presented in Table 1 . Among K. pneumonia strains expressing ESBL activity, high levels of resistance to ampicillin (100 %), cefazolin (100 %), ceftriaxone (100 %), cefuroxime (100 %), and cefepime (95.7 %) were observed. Tested strains of K. pneumoniae were susceptible to imipenem (69.6 %) and meropenem (69.6 %). All E. coli ESBLpositive strains were resistant to ampicillin (intrinsic resistance), cefazolin, cefuroxime, ceftriaxone, and cefepime. Furthermore, ESBL-positive E. coli strains were highly susceptible to meropenem (100 %) and imipenem (100 %). Additionally, other Enterobacteriaceae ESBL-positive strains were completely resistant to ampicillin, cefazolin, and cefuroxime. High activity against other Enterobacteriaceae was shown by ceftriaxone (50 %), cefepime (50 %), imipenem (100 %), and meropenem (100 %) ( Table 3) . Our epidemiological data show a dramatic increase in antimicrobial resistance. Addi tionally, more and more studies show continuous evolution of resistance to β-lactams and other groups of antibiotics in the bacteria of the Enterobacteriaceae family [6-16, 18, 19] .
The constant increase of simultaneous resistance to various classes of antibiotics significantly reduces the possibility of therapeutic treatment of infections caused by ESBLproducers [6-10, 12, 14, 15, 18] . That prompted us to analyze the level of resistance among ESBL-positive tested strains.
ESBL-producers revealed high resistance to antibiotic groups other than β-lactams. The results of our study are in line with some global reports [17, 20] . Our analysis showed a significant degree of ESBL-positive K. pneumoniae resistance to such antibiotics as ofloxacine, levofloxacin, trimethoprim/sulfamethoxazole and ciprofloxacin. The percentages of resistant strains were, respectively, 60.9 %, 60.9 %, 60.9 %, and 52.2 %. E. coli ESBL-positive strains appeared to be resistant to such antibiotics as ciprofloxacin (75 %), levofloxacin (25 %), and ofloxacine (25 %) ( Table 3) .
ESBL-positive strains showing simultaneous resistance to β-lactamases and antibiotics of other groups are defined as multidrug-resistant strains [1, 2] . Global spread of multidrugresistant strains as an etiological factor of infections is described in numerous reports . Characteristic location of genes responsible for resistance is the reason contributing to the prevalence of this phenomenon. Genes encoding β-lactamases are often located in mobile genetic elements such as plasmids, allowing horizontal transfer of these genes between bacteria of Enterobacteriaceae species and non-fermenting bacteria [3] .
In Enterobacteriaceae, resistant genes responsible for resistance to different groups of antibiotics are often located on the same plasmids in a close neighborhood and, thus can be transmitted at the same time to other bacteria [21] .
The ESBL-producing pathogens identified by phenotypic methods were also analyzed by using PCR methods. Of 30 ESBL isolates, 6.6 % harbored multiple bla genes simultaneously and the prevalence of bla TEM was as high as 70.0 %, followed by bla SHV at 46.6 %, and bla CTX-M at 46.6 %. The majority of the TEMpositive isolates were K. pneumoniae (81.8 %), E. coli (50.0 %), and other Enterobacteriaceae, (33.1 %); however, all CTX-M and SHV positive isolates were K. pneumoniae (50.0 % and 59.0 % respectively). Furthermore, all three bla genes (TEM, SHV, and CTX-M) were detected in only 9.0 % of K. pneumoniae isolates, while two genes (SHV/CTX-M) were present in 9.0 % of K. pneumoniae, with TEM/ CTX-M being present in 22.5 % of K. pneumoniae and TEM/SHV being detected in 45.5 % of K. pneumoniae, and 33.3 % in other Enterobacteriaceae isolates (Table 1 , Fig. 1 ).
Conclusions
Compared with previous data from other geographical regions, our study shows relatively low prevalence (10.9 %) of ESBL-producing Enterobacteriaceae. Though lower than in other countries and regions, our results suggest that there is sufficient global infection burden to warrant public health interventions. Notably, majority of isolates were multi-drug resistant and belonged to TEM plasmid-type. The emergence of TEM producing Enterobacteriaceae isolates is of major concern and necessitates further control and research in this area. As meropenem shows good activity against these ESBL producers, it should be restricted for managing patients with suspected Gramnegative bacterial infections with ESBL production. Additionally, antimicrobial control and early detection by active surveillance in combination with effective infection monitoring programs and methods are key steps for reducing or controlling the spread of ESBLpositive hospital-acquired infections in Ukraine.
